10–16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those treated with platinum-based chemotherapy (CT) doublets. Our aim is to perform a real-world survival analysis of patients treated with TKI as first-line therapy at the Hospital of Leon (CAULE) in Spain. The impact on global survival rates and responses to clinical and histopathological factors were also analyzed.
Material and methods
We retrospectively reviewed patients diagnosed with EGFR-mutated NSCLC who received treatment with EGFR-TKI in the Department of Oncology at the University of Leon Health Center complex between March 2011 and June 2018. Data was analyzed with Kaplan-Meier and Cox regression models to show overall survival (OS), progression-free survival (PFS), and the associated variables.
Results
53 patients were included in the study, 50% (n = 27) were treated with gefitinib, 32% (n = 18) with erlotinib and 10% (n = 6) with afatinib. The median OS and PFS were 27.7 months (95% CI: 21–33.8 months) and 18 months (95% CI 14.25–21.89 months), respectively. The variables associated with OS and with PFS were exon19 deletion as a protective factor and presence of extrathoracic metastasis as a risk factor. The most frequent adverse effects were rash, diarrhea, asthenia, and conjunctivitis.
Conclusions
Real-world analysis of this data confirms that treatment with TKI is beneficial for patients diagnosed with EGFR-mutated NSCLC. Our OS outcomes were similar to those reported in clinical trials.
FerlayJColombetMSoerjomataramI, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer2019; 144: 1941–1953.
2.
AllemaniCMatsudaTDi CarloV, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet2018; 391: 1023–1075.
3.
TravisWDBrambillaERielyGJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol2013; 31: 992–1001.
4.
KrisMGJohnsonBEBerryLD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA2014; 311: 1998–2006.
5.
BronteGRizzoSLa PagliaL, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev2010; 36 : S21–S29.
6.
GazdarAF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene2009; 28: S24–S31.
7.
LindemanNICaglePTBeasleyMB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol2013; 8: 823–859.
8.
FukuokaMWuYLThongprasertS, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol2011; 29: 2866–2874.
9.
MitsudomiTMoritaSYatabeY, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol2010; 11: 121–128.
10.
InoueAKobayashiKMaemondoM, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol2013; 24: 54–59.
11.
ZhouCWuYLChenG, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011; 12: 735–742.
12.
RosellRCarcerenyEGervaisR, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol2012; 13: 239–246.
13.
SequistLVYangJCYamamotoN, et al. Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol2013; 31: 3327–3334.
14.
YangJCHirshVSchulerM, et al. Symptom control and quality of life in LUX-lung 3: a phase III study of Afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol2013; 31: 3342–3350.
15.
YangJCWuYLSchulerM, et al. Afatinib Versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol2015; 16: 141–151.
16.
SoriaJCOheYVansteenkisteJ, et al. Osimertinib in untreated EGFR- mutated advanced non-small-cell lung cancer. N Engl J Med2018; 378: 113–125.
17.
NishinoMJackmanDMHatabuH, et al. New response evaluation criteria in solid tumor (RECIST) guidelines for advanced non-small cell lung cancer: comparision with original RECIST and impact on assessment of tumor response to targeted therapy. Am J Roentgenology2010; 195: W221–W228.
18.
StataCorp. Stata statistical software: release 15. College station, TX: stataCorp LLC, 2017.
19.
BriaEMilellaMCupponeF, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a metaanalysis. Ann Oncol2011; 22: 2277–2285.
20.
PetrelliFBorgonovoKCabidduM, et al.Efficacy of EGFR tyrosine kinase inhibitors in patients With EGFR-mutated Non–small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer2012; 13: 107–114.
21.
LeeCKBrownCGrallaRJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst2013; 105: 595–605.
22.
GuetzGDLandreTUzzanB,et al.Is there a survival benefit of first-line epidermal growth factor receptor tyrosine-kinase inhibitor monotherapy versus chemotherapy in patients with advanced Non-small-cell lung cancer?: A Meta-Analysis. Targ Oncol2016; 11: 41–47.
23.
LeeCKWuYLDingPN, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment With EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol2015; 33: 1958–1965.
24.
RamalingamSSVansteenkisteJPlanchardD, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med2020; 382: 41–50.
25.
HollemanMSvan TinterenHGroenHJ,et al.First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther2019; 12: 1413–1421.
26.
HasegawaYAndoMMaemondoM, et al. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemother. Oncologist2015; 20: 307–315.
27.
BuonerbaCIaccarinoSDolceP, et al. Predictors of outcomes in patients with EGFR-mutated Non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2019; 11(9): pii: E1259.
28.
RielyGJPaoWPhamD, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res2006; 12: 839–844.
29.
ZhangYShengJKangS, et al. Patients with exon 19 deletion were associated with Longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced Non-small cell lung cancer: a meta-analysis. PLoS One2014; 9: e107161.
30.
KuanFCKuoLTChenMC, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer2015; 113: 1519–1528.
31.
Rami-PortaREberhardtWEE. Clinical implications of the innovations in the primary tumour and metastasis of the 8th edition of the TNM classification for lung cáncer. J Thorac Dis2018; 10: S2682 − SS2685.
32.
SakaiKKuramotoJKojimaA, et al. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan. Int J Clin Oncol2019; 24: 1549–1557.
33.
HuangCYChenBHChouWC,et al.Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. J Thorac Dis2018; 10: 2070–2078.
34.
TamuraKNukiwaTGemmaA, et al. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily Afatinib. Int J Clin Oncol2019; 24: 917–926.
35.
LiangHSongXZhangY, et al. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non- small cell lung cancer patients in northern China: a prospective observational study. Thorac Cancer2019; 10: 1521–1532.
36.
LiYAppiusAPattipakaT,et al.Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non– small-cell lung cancer in the USA. PLoS ONE2019; 14: e0209709n.
